Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Blood Pressure Medication Recalls

Recalls of ARBs, ACE inhibitors, beta blockers and other hypertension drugs - the class behind the large valsartan and losartan nitrosamine recalls.

549 recalls in this category, newest first.

Class III · Low risk

Valsartan Tablets USP

Incorrect/Undeclared Excipient: There is a potential an incorrect grade of excipient was used during manufacturing.

Terminated Chemical / undeclared Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-362-90 D-1105-2018
Class III · Low risk

Valsartan Tablets USP

Incorrect/Undeclared Excipient: There is a potential an incorrect grade of excipient was used during manufacturing.

Terminated Chemical / undeclared Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-361-90 D-1104-2018
Class III · Low risk

Valsartan Tablets USP

Incorrect/Undeclared Excipient: There is a potential an incorrect grade of excipient was used during manufacturing.

Terminated Chemical / undeclared Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-360-30 D-1103-2018
Class II · Moderate risk

Lisinopril Tablets USP

Presence of Foreign Substance: Product complaint was received of metal contaminant observed in one tablet.

Terminated Particulate / foreign matter Lupin Pharmaceuticals Inc. NDC 68180-980-03 D-1077-2018
Class II · Moderate risk

Valsartan 320 mg Tablets

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Terminated Nitrosamine impurity RemedyRepack Inc. NDC 61786-0793-19 D-1102-2018
Class II · Moderate risk

Valsartan 80 mg Tablet

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Terminated Nitrosamine impurity RemedyRepack Inc. NDC 61786-0791-19 D-1100-2018
Class II · Moderate risk

Camber Pharmaceuticals

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Completed Nitrosamine impurity Hetero Labs Limited Unit V NDC 31722-748-90 D-1116-2018
Class II · Moderate risk

Camber Pharmaceuticals

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Completed Nitrosamine impurity Hetero Labs Limited Unit V NDC 31722-747-90 D-1115-2018
Class II · Moderate risk

Camber Pharmaceuticals

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Completed Nitrosamine impurity Hetero Labs Limited Unit V NDC 31722-746-90 D-1114-2018
Class II · Moderate risk

Camber Pharmaceuticals

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Completed Nitrosamine impurity Hetero Labs Limited Unit V NDC 31722-745-30 D-1113-2018
Class II · Moderate risk

Valsartan 320 mg tablets

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Terminated Nitrosamine impurity Bryant Ranch Prepack Inc. NDC 71335-0567-2 D-1029-2018
Class II · Moderate risk

Valsartan 320 mg tablets

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Terminated Nitrosamine impurity Bryant Ranch Prepack Inc. NDC 63629-6905-1 D-1028-2018
Class II · Moderate risk

Valsartan 80 mg tablets

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Terminated Nitrosamine impurity Bryant Ranch Prepack Inc. NDC 63629-6922-2 D-1027-2018
Class II · Moderate risk

Valsartan tablets 160 mg

Carcinogen impurity detected in API used to manufacture drug product.

Terminated Nitrosamine impurity H J Harkins Company Inc dba Pharma Pac NDC 43547-0369-09 D-1022-2018
Class II · Moderate risk

Valsartan

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Terminated Nitrosamine impurity Northwind Pharmaceuticals LLC D-1098-2018
Class II · Moderate risk

Valsartan

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Terminated Nitrosamine impurity Northwind Pharmaceuticals LLC D-1097-2018